Publication

Breast cancer is the most common invasive cancer in women worldwide. According to estimates nearly 480,000 women died because of breast cancer in 2008. Therefore it is increasingly important to develop a method, which identifies breast cancer at an early stage, so that a therapy can be induced very fast. The Interreg IV-A project MICROBIOMED (MICROtechnologies for BIOMEDical applications) was funded to achieve this goal by developing an in vitro diagnostic tool.

Significant advances in the field of biomedical engineering over the last few years have increased the standard of medical care to an incomparabel
level.

In March 2012, L1 channel made a presentation of the Hematology Department of the University Hospital of Maastricht headed by Gerard Bos in order to highlight its involvement in the MicroBioMed project.

Edited by : AZM-MUMC+, Gerard Bos

Approximately one out of ten women in Europe is concerned with breast cancer. The Netherlands, Belgium and Germany are among countries with the highest incidence rate. Current screening methods have proven themselves to be efficient but also to detect only late stage cancers. With the support of Interreg, MicroBioMed project aims at developing a new, early-stage and rapid diagnostic tool.